About
This page is intended for participants in the ABCESS2 study to provide them with the following information:
- The overall results of the ABCESS2 study
- the ABCESS2 information leaflet and information on the protection of personal data
- New research re-using the samples and data collected in the ABCESS2 study.
Date of last update: 17/02/2025
The ABCESS2 study:
ABCESS2 is a study investigating a new antibiotic therapy to treat Verneuil’s disease (Hidrosadenitis Suppurativa) in stage 2 patients.
There is a strong unmet need in HS treatment. The pathophysiology of HS is most likely multifactorial, including genetic, immune and microbiological factors. Specific pathobionts in HS lesions have been identified by our team. Antibiotics are widely used to treat HS and clinical remission of the disease has been obtained prospectively in 14/17 Hurley stage 2 patients at the Institut Pasteur Medical Center with an adapted antibiotic strategy.
The objective is to demonstrate the superiority of a 3–week course of a ceftriaxone+metronidazole treatment followed by 3 weeks of a rifampin+moxifloxacin+metronidazole combination, then 6 weeks of rifampin+moxifloxacin (experimental treatment) over a 12-week course of a tetracycline derivative in patients with Hurley stage 2 HS at week 12 in a multicentric randomized double-blind phase 3 trial.
Collaborators:
-
- Centre Médical de l’Institut Pasteur, Paris
- Hôpital Saint Joseph, Paris
- Hôpital de la Timone, Marseille
- CHU de Rouen
- INVOLvE : Investigation et volontaires en santé humaine, Institut Pasteur
- CHIP : Collections Santé Humaine de l’Institut Pasteur
- PC-RC: Pôle de Coordination de la Recherche Clinique, Institut Pasteur
- Laboratoire de Microbiologie du CHU de Caen
Contact details :
–> Institut Pasteur Medical Centre: abcess2@pasteur.fr
What is the aim of this study?
The aim of the study is to demonstrate the efficacy of this combination of antibiotics (ceftriaxone, rifampicin, moxifloxacin and metronidazole). Efficacy will be assessed at several levels: clinical and microbiological efficacy, but also the effectiveness of the treatment on quality of life and pain. The use of additional treatments and relapses after clinical remission will also be assessed.
If the efficacy of this therapy is demonstrated, the benefits could be collective for all people suffering from Verneuil disease. This will make it possible to standardise practices and establish new recommendations. In this way, if the treatment proves effective, Verneuil disease patients will be better cared for.
Who can participate?
Adult patients aged between 18 and 59 with Hurley stage 2 hidrosadenitis suppurativa are likely to be eligible to take part in the ABCESS2 study.
What does participation in the study involve?
This study is double-blind. This means that neither the patient nor the doctor knows which treatment has been assigned.
A random draw will determine the treatment allocated to the patient, either the study treatment or the reference treatment.
This methodology is necessary to objectively assess the efficacy of the study treatment.
Patients will undergo a medical examination before the start of the study, which will determine whether or not they can take part. Participation in the study will last a maximum of 1 year and 2 months, and will involve an inclusion visit and 6 other visits. These visits are scheduled according to the usual management of patients with stage 2 HS.
The inclusion visit will be carried out as part of the usual follow-up.
Treatment allocation may take place at the same time as the inclusion visit or within 30 days of the inclusion visit.All visits will take place at the medical centre where patients are being treated for the disease. Treatments will be given at the time of the visits.
With the exception of ceftriaxone and its placebo, which must be injected intramuscularly for the first 3 weeks, the other treatments consist of capsules to be taken as explained by the investigating doctor and in the patient booklet that will be handed out.
Would you like to take part or obtain further information?
You will find the detailed information documents for the ABCESS2 study by clicking here (Information notice).
ABCESS2 study results and information documents
Documents to come